Arkolith/Insider Trading/ATNM/Form 4

O'Loughlin Steve

Chief Financial OfficerActinium Pharmaceuticals, Inc. (ATNM) · full profile →Form 4 · filed Apr 2, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
9
0 non-derivative · 9 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 31, 2025Disposed to issuer(D)253K—$00
Mar 31, 2025Disposed to issuer(D)256K—$00
Mar 31, 2025Disposed to issuer(D)107K—$00
Mar 31, 2025Disposed to issuer(D)59K—$00
Mar 31, 2025Disposed to issuer(D)13K—$00
Mar 31, 2025Disposed to issuer(D)9K—$00
Mar 31, 2025Disposed to issuer(D)3K—$00
Mar 31, 2025Disposed to issuer(D)2K—$00
Mar 31, 2025Disposed to issuer(D)3K—$00

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001213900-25-028225) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML